Jones D J, Holt S D, Surtees P, Davison D J, Coptcoat M J
Princess of Wales Royal Air Force Hospital, Ely, Cambridgeshire.
Ann R Coll Surg Engl. 1990 Sep;72(5):296-8.
In an attempt to define the efficacy of danazol in the treatment of idiopathic gynaecomastia, 55 patients were enrolled into a randomised double-blind comparison of danazol 200 mg twice daily for 3 months against placebo. The results of 52 patients were evaluated, three patients being excluded because of protocol violations. Danazol improved breast tenderness to a significantly greater degree than did placebo (P = 0.022, danazol vs placebo) and was associated with statistically significant improvement in the degree of gynaecomastia and in its measured size (P less than 0.05). The intended management of patients who had received danazol was less likely to be surgery compared to the placebo group when assessed at the end of treatment (27% vs 50%). Minor side effects were common in both groups, but significant weight gain was noted in the danazol group alone. If there is no urgent need for rapid resolution of gynaecomastia, danazol 200 mg twice daily can provide effective control of symptoms and may obviate the need for surgery.
为了确定达那唑治疗特发性男性乳房肥大症的疗效，55例患者被纳入一项随机双盲对照试验，比较每日两次服用200毫克达那唑，持续3个月与服用安慰剂的效果。对52例患者的结果进行了评估，3例患者因违反方案被排除。达那唑改善乳房压痛的程度明显大于安慰剂（P = 0.022，达那唑与安慰剂相比），并且与男性乳房肥大症的程度及其测量大小的统计学显著改善相关（P < 0.05）。在治疗结束时评估，接受达那唑治疗的患者接受手术治疗的可能性低于安慰剂组（27% 对50%）。两组均常见轻微副作用，但仅达那唑组出现明显体重增加。如果对迅速消除男性乳房肥大症没有迫切需求，每日两次服用200毫克达那唑可有效控制症状，且可能无需进行手术。
